Session » Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1859

Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study

8:30AM-10:30AM: Abstract Number: 1840

Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients

8:30AM-10:30AM: Abstract Number: 1850

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON

8:30AM-10:30AM: Abstract Number: 1854

Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience

8:30AM-10:30AM: Abstract Number: 1851

Early Intervention with Immunomodulators Leads to Better Outcomes in Patients with Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1846

Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial

8:30AM-10:30AM: Abstract Number: 1844

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial

8:30AM-10:30AM: Abstract Number: 1861

Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin

8:30AM-10:30AM: Abstract Number: 1849

False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center

8:30AM-10:30AM: Abstract Number: 1838

Further Construct Validation of the

8:30AM-10:30AM: Abstract Number: 1852

Healthcare Utilization and Economic Burden in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1839

Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study

8:30AM-10:30AM: Abstract Number: 1837

KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD

8:30AM-10:30AM: Abstract Number: 1836

Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1843

Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

8:30AM-10:30AM: Abstract Number: 1842

Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease

8:30AM-10:30AM: Abstract Number: 1841

Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases

8:30AM-10:30AM: Abstract Number: 1853

Scleroderma Presentation in the Canadian Scleroderma Research Group Indigenous Population

8:30AM-10:30AM: Abstract Number: 1856

Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc

8:30AM-10:30AM: Abstract Number: 1858

Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort

8:30AM-10:30AM: Abstract Number: 1847

Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1845

Six-minute Walk Test as a Prognostic Marker in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1860

Three Distinct Transcriptional Profiles of Monocytes Correlate with Disease Activity in SSc Patients

8:30AM-10:30AM: Abstract Number: 1857

Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1848

Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1855

Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].